title: Treatment of transplant-eligible patients with multiple myeloma in 2014.
abstract: Induction regimens containing a proteasome inhibitor and/or immunomodulatory agent with dexamethasone result in rapid disease control before autologous stem cell transplantation (ASCT). ASCT followed by consolidation and/or maintenance further improves depth of response following effective induction. Overall survival of transplant-eligible patients has been extended with modern therapeutic strategies. The optimal timing of ASCT and methods to prevent relapse following ASCT are under active investigation. Different patient populations may benefit differentially from currently available treatments.
authors.affiliation: Adult BMT Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA.
authors.forename: Heather
authors.initials: H
authors.lastname: Landau
authors.affiliation: Adult BMT Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA. Electronic address: sagiralt@gmail.com.
authors.forename: Sergio
authors.initials: S
authors.lastname: Giralt
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000008:administration & dosage; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods; D009101:Multiple Myeloma / Q000628:therapy*; D033581:Stem Cell Transplantation / Q000379:methods*; D016019:Survival Analysis; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D003907:Dexamethasone
keywords: Corticosteroids; Dexamethasone; Melphalan; Stem cell transplantation; Toxicity